Intensifying competition in the global biosimilars space and a temporary drop in its factory utilization rate took a toll on Celltrion's earnings in the third quarter, but analysts still expect a rosy outlook next year amid the expected US launches of biosimilar rituximab and trastuzumab, and the first subcutaneous version of Remsima on the horizon in Europe.

Takeda is hoping to start 2019 with a bang, saying its huge acquisition of Shire might become a done deal as early as January 8. Speculation continues meanwhile on possible post-merger divestments to help pay down associated debt. 

UnitedHealthcare offers HIV-infected patients a financial incentive to switch to lower-cost therapy, including generic TDF, but analysts suspect the savings won’t be enough to encourage much switching away from Gilead’s single-tablet regimens.

Yupelri was approved by the US FDA as the first nebulized long-acting muscarinic antagonist for once-daily treatment of chronic obstructive pulmonary disease.

Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline over the next few years, liberated from the constraints of portfolio management.

The US bioventure Accera, hit by a Phase III failure for its lead candidate last year, is expanding into Asia and renaming itself as it remains hopeful of progressing its core investigational asset in a targeted population of Alzheimer’s disease patients.

European research-based pharma group proposes reconsideration of Japan’s revised pricing system, warning it is already affecting corporate R&D decisions and will stifle industry investment, innovation and patient access to new therapies if incentives are not improved.

It took NICE nearly three years to offer routine access to Lenvima for thyroid cancer but it has taken just three months from European approval to recommend the drug for advanced or unresectable hepatocellular carcinoma.

A London conference was told that Chinese trends in modernizing healthcare and life sciences innovation will soon produce high-quality 'made in China' medicines for global export.

Sweden's life science industry is a key component of the Scandinavian country's economy. New life science companies emerge there every year. Growing shipments to China and Japan by Swedish companies reflect the duo’s increasing importance as export markets, especially in relation to the US and the European Union. And while the UK has hitherto been regarded as a stepping stone to foreign markets, worries over what Brexit will mean for future business and opportunities is prompting players to increasingly look to the US to set up operations.

China’s artificial intelligence-powered healthcare ambition takes a new form, a 24-hour health clinic complete with a medicine dispenser that may eventually be coming to a city corner near you. Pharma companies are also continuing to build digital health services in the country as part of the health technology push.

CVOT results for Amarin's fish-oil pill show an unprecedented reduction in cardiovascular deaths. While questions have been raised about an LDL increase in the placebo group, an investigator says the overall results are too good to be explained by a well-known mineral oil effect.